Want to see AU:CHM full AI Analyst Report?
Total Valuation
Chimeric Therapeutics Ltd. has a market cap or net worth of AU$442.39K. The enterprise value is AU$3.44M.
Market CapAU$442.39K
Enterprise ValueAU$3.44M
Share Statistics
Chimeric Therapeutics Ltd. has 147,461,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding147,461,980
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chimeric Therapeutics Ltd.’s return on equity (ROE) is 2.44 and return on invested capital (ROIC) is 120.57%.
Return on Equity (ROE)2.44
Return on Assets (ROA)-14.71
Return on Invested Capital (ROIC)120.57%
Return on Capital Employed (ROCE)1.10
Revenue Per Employee0.00
Profits Per Employee-6.27M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chimeric Therapeutics Ltd. is ―. Chimeric Therapeutics Ltd.’s PEG ratio is 0.00513.
PE Ratio―
PS Ratio0.00
PB Ratio-0.26
Price to FCF0.00
Price to Operating Cash Flow>-0.01
PEG Ratio0.00513
Income Statement
In the last 12 months, Chimeric Therapeutics Ltd. had revenue of 0.00 and earned -18.81M in profits. Earnings per share was -0.61.
Revenue0.00
Gross Profit0.00
Operating Income-8.36M
Pretax Income-18.79M
Net Income-18.81M
EBITDA-8.36M
Earnings Per Share (EPS)-0.61
Cash Flow
In the last 12 months, operating cash flow was -10.78M and capital expenditures 6.94M, giving a free cash flow of -3.84M billion.
Operating Cash Flow-10.78M
Free Cash Flow-3.84M
Free Cash Flow per Share-0.03
Dividends & Yields
Chimeric Therapeutics Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change-93.53%
50-Day Moving Average0.04
200-Day Moving Average―
Relative Strength Index (RSI)7.46
Average Volume (3m)983.95K
Important Dates
Chimeric Therapeutics Ltd. upcoming earnings date is Feb 26, 2027, Before Open (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateFeb 26, 2027
Ex-Dividend Date―
Financial Position
Chimeric Therapeutics Ltd. as a current ratio of 0.12, with Debt / Equity ratio of -8.80%
Current Ratio0.12
Quick Ratio0.12
Debt to Market Cap0.34
Net Debt to EBITDA0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Chimeric Therapeutics Ltd. has paid 22.14K in taxes.
Income Tax22.14K
Effective Tax Rate>-0.01
Enterprise Valuation
Chimeric Therapeutics Ltd. EV to EBITDA ratio is -0.23, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-0.23
EV to Free Cash Flow0.00
EV to Operating Cash Flow-0.17
Balance Sheet
Chimeric Therapeutics Ltd. has AU$800.14K in cash and marketable securities with AU$679.85K in debt, giving a net cash position of AU$120.30K billion.
Cash & Marketable SecuritiesAU$800.14K
Total DebtAU$679.85K
Net CashAU$120.30K
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share-AU$0.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Chimeric Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast-46.98%